Quest Diagnostics Inc
DGX- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001022079
In the last 90 days, Quest Diagnostics Inc insiders filed 0 open-market purchases and 6 sales; 1,142 institutions reported holding it in 13F filings for Q3 2026, worth $23.9B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 24, 2026, 1:06 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 30, 2025 | Feb 1, 2024 | Feb 2, 2023 | Jan 12, 2022 |
| Revenue | $11.0B | $9.87B | $9.25B | $9.88B | $10.8B |
| Cost of revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B |
| Selling, general and administrative | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B |
| Interest expense | – | – | $163.0M | $148.0M | $152.0M |
| Income tax | $314.0M | $273.0M | $248.0M | $264.0M | $597.0M |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B |
| EPS, basic | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 |
| EPS, diluted | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Weighted shares, basic | 111.0M | 111.0M | 112.0M | 116.0M | 125.0M |
| Weighted shares, diluted | 113.0M | 113.0M | 113.0M | 118.0M | 128.0M |
| Margins and growth | |||||
| Operating margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Net margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% |
| Revenue growth, year over year | +11.8% | +6.7% | −6.4% | −8.4% | +14.3% |
| Net income growth, year over year | +13.9% | +2.0% | −9.7% | −52.6% | +39.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 30, 2025 | Feb 1, 2024 | Feb 2, 2023 | Jan 12, 2022 |
| Cash and equivalents | $420.0M | $549.0M | $686.0M | $315.0M | $872.0M |
| Accounts receivable | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B |
| Inventory | $189.0M | $188.0M | $190.0M | $192.0M | $208.0M |
| Total current assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B |
| Property, plant and equipment | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B |
| Intangible assets | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B |
| Total assets | $16.2B | $16.2B | $14.0B | $12.8B | $13.6B |
| Short-term debt | $504.0M | $602.0M | $303.0M | $2.00M | $2.00M |
| Total current liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B |
| Long-term debt | $5.17B | $5.62B | $4.41B | $3.98B | $4.01B |
| Shareholders' equity | $7.21B | $6.81B | $6.34B | $5.93B | $6.48B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 30, 2025 | Feb 1, 2024 | Feb 2, 2023 | Jan 12, 2022 |
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B |
| Capital expenditures | $527.0M | $425.0M | $408.0M | $404.0M | $403.0M |
| Free cash flow | $1.36B | $909.0M | $864.0M | $1.31B | $1.83B |
| Depreciation and amortization | $570.0M | $493.0M | $439.0M | $437.0M | $408.0M |
| Stock-based compensation | $88.0M | $88.0M | $77.0M | $77.0M | $79.0M |
| Dividends paid | $353.0M | $331.0M | $314.0M | $305.0M | $309.0M |
| Share buybacks | $450.0M | $151.0M | $275.0M | $1.41B | $2.20B |
| Investing cash flow | -$631.0M | -$2.55B | -$1.06B | -$543.0M | $21.0M |
| Financing cash flow | -$1.39B | $1.08B | $160.0M | -$1.73B | -$2.54B |
| Net change in cash | -$129.0M | -$137.0M | $371.0M | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.8% | 0.9% | 0.8% | 0.8% | 0.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 15, 2026 | 110.0M | −1.1% | SEC |
| Jul 15, 2026 | 110.4M | −1.3% | SEC |
| Apr 15, 2026 | 110.7M | −0.8% | SEC |
| Feb 2, 2026 | 109.9M | −1.0% | SEC |
| Oct 15, 2025 | 111.2M | −0.3% | SEC |
| Jul 15, 2025 | 111.8M | +0.5% | SEC |
| Apr 15, 2025 | 111.6M | +0.5% | SEC |
| Jan 31, 2025 | 111.0M | +0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.